Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Mod GRF 1-29 (CJC-1295 no DAC)
Overview
Modified GRF 1-29 is a synthetic analogue of growth hormone releasing hormone (GHRH) comprising 29 amino acids with four amino acid substitutions to enhance stability. These modifications increase resistance to enzymatic degradation compared to native GHRH while maintaining receptor affinity and biological activity.
Mechanism of Action
The compound stimulates pulsatile growth hormone release from the anterior pituitary without the half-life extension conferred by drug affinity complex technology.
Research Summary & Key Findings
Preclinical studies have demonstrated enhanced growth hormone secretion and improved pharmacokinetic stability relative to native GHRH. No formal clinical trials have been published in peer-reviewed literature, and the compound lacks regulatory evaluation by major health authorities. Its use has been primarily documented in performance enhancement contexts outside approved therapeutic settings.
Clinical Status
Mod GRF 1-29 (CJC-1295 no DAC) is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
Administration Routes
References
Primary literature
- PubMed: "Mod GRF 1-29"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Mod GRF 1-29"
Registered interventional and observational studies, including status and phase.
- PubChem: "Mod GRF 1-29"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Hormone
CJC-1295
In Clinical TrialsA synthetic analog of growth hormone-releasing hormone (GHRH) with a Drug Affinity Complex (DAC) that binds to albumin, ...
View detailsIpamorelin
In Clinical TrialsA highly selective growth hormone secretagogue that acts on ghrelin/GHS receptors in the pituitary gland to stimulate GH...
View detailsSermorelin
FDA ApprovedA synthetic 29-amino acid analog of GHRH representing the shortest fully functional fragment of the native 44-amino acid...
View detailsTesamorelin (Egrifta)
FDA ApprovedA synthetic GHRH analog consisting of the 44-amino acid sequence of human GHRH with a trans-3-hexenoic acid modification...
View detailsNo lawful pathway today
Mod GRF 1-29 (CJC-1295 no DAC) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.